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Abstract
Molecular events preceding the development of hepatocellular
carcinoma were studied in the Mdr2-knockout (Mdr2-KO)
mice. These mice lack the liver-specific P-glycoprotein
responsible for phosphatidylcholine transport across the
canalicular membrane. Portal inflammation ensues at an
early age followed by hepatocellular carcinoma development
after the age of 1 year. Liver tissue samples of Mdr2-KO mice
in the early and late precancerous stages of liver disease were
subjected to histologic, biochemical, and gene expression
profiling analysis. In an early stage, multiple protective
mechanisms were found, including induction of many anti-
inflammatory and antioxidant genes and increase of total
antioxidant capacity of liver tissue. Despite stimulation of
hepatocyte DNA replication, their mitotic activity was blocked
at this stage. In the late stage of the disease, although the total
antioxidant capacity of liver tissue of Mdr2-KO mice was
normal, and inflammation was less prominent, many protec-
tive genes remained overexpressed. Increased mitotic activity
of hepatocytes resulted in multiple dysplastic nodules, some
of them being steatotic. Expression of many genes regulating
lipid and phospholipid metabolism was distorted, including
up-regulation of choline kinase A, a known oncogene. Many
other oncogenes, including cyclin D1, Jun, and some Ras
homologues, were up-regulated in Mdr2-KO mice at both
stages of liver disease. However, we found no increase of
Ras activation. Our data suggest that some of the adaptive
mechanisms induced in the early stages of hepatic disease,
which protect the liver from injury, could have an effect in
hepatocarcinogenesis at later stages of the disease in this
hepatocellular carcinoma model. (Cancer Res 2006; 66(8): 4001-10)
Introduction
Hepatocarcinogenesis has many features that are common in
mice and humans. Various mouse models of hepatocellular
carcinoma, including knockout and transgenic animals, have been
used to study the molecular mechanisms of liver cancer. Compar-
ative analysis of global gene expression patterns of different mouse
hepatocellular carcinoma models and human hepatocellular
carcinoma samples showed that most mouse hepatocellular
carcinomas are similar to specific subgroups of human hepatocel-
lular carcinomas and thus may be useful in modeling studies (1).
To study the molecular mechanisms of hepatocellular carcinoma
development and to find candidate genes for gene therapy
intervention in the early stages of the disease, we did intensive
analysis of liver tissues of the Mdr2-knockout (Mdr2-KO) mice
in the precancerous stages of liver disease. These mice lack the
liver-specific P-glycoprotein responsible for phosphatidylcholine
transport across the canalicular membrane (2). The absence of
phospholipids from bile leads to bile regurgitation into the portal
tracts (3), causing portal inflammation that ensues at an early age
followed by slowly developing hepatocellular carcinoma, which, in
this regard, mimics the human disease (4).
In the present study, we investigated different signaling pathways
associated with precancerous stages of liver disease in the Mdr2-
KO model. Liver tissue samples of Mdr2-KO and control Mdr2-
heterozygous mice at ages 3 and 12 months were subjected to
histologic, biochemical, and gene expression profiling analysis.
Results revealed complex interactions between signaling pathways
that control inflammatory reactions, response to oxidative stress,
lipid metabolism, and cell proliferation. These findings suggest that
induction of multiple adaptive mechanisms protecting liver tissue
in the early stages of the disease as well as progressively disturbed
lipid and phospholipid metabolism may have an effect in
hepatocellular carcinoma development in the later stages of liver
disease in Mdr2-KO mice.
Materials and Methods
Mice. Founders of the FVB.129P2-Abcb4
tm1Bor (Mdr2-KO; old name
FVB.129P2-Pgy2
tm1Bor) and the wild-type FVB/NJ mice were purchased
from The Jackson Laboratory (Bar Harbor, ME). Colonies of both strains
were maintained under specific pathogen-free conditions in the Animal
Facility of The Hebrew University Medical School. The F1 hybrids produced
by breeding of a FVB.129P2-Abcb4
tm1Bor male and a FVB/NJ female were
used as age-matched controls.
Harvesting of mouse liver tissue. Nonfasting male Mdr2-KO or control
heterozygous mice were anesthetized with isoflurane and sacrificed by
cervical dislocation. Livers were rapidly excised and weighed; part of the left
lobe was fixed in 4% buffered formaldehyde for histologicanalysis, and the
remaining liver tissue was quickly frozen in liquid nitrogen and stored at
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Research Article80jC until use. All mice were operated at the same time interval between
12:00 a.m. and 15:00 p.m.
Blood analysis. Blood was collected by orbital bleeding. Levels of liver
enzymes in sera were determined using Reflotron (Roche, Mannheim,
Germany).
Gene expression profiling. Total RNA was isolated from frozen liver
tissues with Trizol reagent (Invitrogen, Carlsbad, CA) as described by the
manufacturer. Gene expression profiling was done using Affymetrix (Santa
Clara, CA) Mouse Genome Array 430A (f22,000 genes). Data were analyzed
using Microarray Analysis Suite version 5 (MAS 5.0; Affymetrix), Matlab
software (MathWorks, Natick, MA), and superparamagnetic (SPC) clustering
algorithm (5) as described in Supplementary Data.
Deletions in mitochondrial DNA. The D1 deletion in mitochondrial
DNA (mtDNA), which accumulates in livers of aging mice, was detected by
semiquantitative reverse transcription-PCR (RT-PCR) using primers ‘‘mtD1’’
flanking the deletion ends (Supplementary Table S1) and total liver DNA as
a template as described in ref. 6. A stable fragment of mtDNA that does not
produce deletions with age was used as control (primers ‘‘mtDNA’’).
Protein oxidation. The degree of protein oxidation in liver tissue was
evaluated using the ‘‘Oxyblot’’ kit (Chemicon, Pittsburgh, PA) as recom-
mended by the manufacturer. The method is based on immunodetection of
carbonyl groups that are a hallmark of the oxidative status of proteins.
Total antioxidant capacity. The total antioxidant capacity of liver
tissues was evaluated by modifying the method described by Kawagoe
and Nakagawa (7). Total antioxidant capacity of liver tissue is inversely
proportional to its IC50, which was estimated by adding to serial
dilutions of liver extracts the hydrophilic free radical initiator 2,2V -
azobis(2-amidinopropane) dihydrochloride (AAPH; Wako Chemicals,
Neuss, Germany), and luminol as a chemiluminescence amplifier.
Percentage of inhibition for each dilution was calculated as the decrease
of luminescence from that of the most diluted sample. The data were
normalized to protein concentration measured by the Bradford method.
The IC50 was defined based on polynomial regression of the inhibitory
curves. Chemiluminescence was measured by a ‘‘Mithras LB 940’’
luminometer (Berthold Technologies, Bad Wildbad, Germany).
Ras activation assay. Detection of Ras-GTP complexes by pull-down
assay with glutathione S-transferase (GST)-Raf1-RBD protein was done
using the EZ-Detect Ras activation kit (Pierce, Rockford, IL) as described by
the manufacturer.
Statistical analysis. The total antioxidant capacity of liver tissue, the
liver-to-body weight relation, and the liver mitoticac tivity were evaluated
with the two-tailed t test. The age-associated changes in serum
concentration of liver enzymes were evaluated with the one-tailed t test.
Results
Characterization of Mdr2-KO mice. We used the Mdr2-KO
strain FVB.129P2-Pgy2
tm1Bor (4), which develops liver tumors at age
15 months with f100% efficiency.
6 As a control, we used its hybrid
with the parental strain FVB/N (F1 generation only). Although
these hybrid heterozygotes Mdr2(+/) had a genotype highly
similar to that of Mdr2-KO, they were phenotypically healthy and
did not develop liver tumors over the 2-year monitoring period. To
follow developmental differences in the precancerous stages, we
studied liver tissue and sera from Mdr2-KO and control Mdr2(+/)
males at ages 3, 6, 9, and 12 months. The Mdr2-KO strain showed
significantly elevated serum levels of liver enzymes (Fig. 1A) and
mild hepatomegaly (Fig. 1B) during all precancerous disease stages.
Hepatocyte proliferation in Mdr2-KO mice increased dramatically
between age 6 and 9 months (Fig. 1C). At the age of 12 months,
most Mdr2-KO mouse livers had one or two visible steatotic
nodules measuring 1 to 3 mm in diameter (Fig. 2A).
Analysis of gene expression profiling. RNA samples from
livers of Mdr2-KO and control heterozygous 3- and 12-month-old
mice (three males per experimental group) were subjected to
genome-scale gene expression profiling. The gene expression values
were extracted with MAS 5.0 software and analyzed by cluster
analysis, fold change filtering, and statistical tests. The cluster
analysis of the expression data resulted in division of samples
according to the experimental groups (Fig. 3A). The SPC cluster
analysis (5, 8) of genes applied alone or in combination with gene
prefiltering, based on differential expression between the experi-
mental groups, revealed several gene clusters characterized by
common expression patterns and similar functions. Clusters
containing genes, which were progressively up-regulated from
ages 3 to 12 months, were enriched with genes involved in cell
proliferation.
Evaluation of differential expression of genes between mutants
and heterozygotes of both ages using fold change filters (the 2- or
1.8-fold difference) showed a significant decrease in the number
of differentially expressed genes from ages 3 to 12 months. The
difference was more dramatic for down-regulated genes (Fig. 3B).
Functional categories of genes with at least 2-fold differential
expression between mutants and controls are shown in Table 1.
Statistical analysis of Gene Ontology definitions done with EASE
online tool revealed that, at both ages, the processes related to
immune and inflammatory responses and to DNA replication were
the most significant.
Histology and analysis of immune/inflammatory genes and
cells. Pathologic scores of H&E-stained liver sections from 3- and
12-month-old Mdr2-KO mice were significantly higher than those
of control mice (Supplementary Table S2). Livers of 3-month-old
Mdr2-KO mice had characteristic portal inflammation, portal tract
expansion due to bile duct hyperplasia, and fibrosis with early
septal formation (Fig. 2B). At 12 months, inflammatory infiltrates
in the portal tracts of Mdr2-KO livers were less pronounced
(Supplementary Fig. S1B), and the lobular architecture was
disrupted, causing difficulty in detecting parenchymal fibrosis.
Focal accumulations of inflammatory cells were observed within
lobular areas, suggesting ongoing inflammation.
Inflammatory cell infiltrates were further characterized by
staining for monocytes/macrophages (F4/80) and neutrophil
myeloperoxidase. In livers of 3-month-old mutants, a moderate
increase in myeloperoxidase-positive cells was observed in the
inflamed portal tracts (data not shown). However, at 3 months,
many F4/80-positive cells were observed in the portal tracts of
Mdr2-KO mice relative to control mice (Fig. 2B), suggesting a
massive infiltration of monocytes/macrophages. These patterns
prevailed in samples taken from 12-month-old mice, although the
numbers of inflammatory cells in the portal tracts seemed reduced
in comparison with those observed at 3 months (data not shown).
About 10% of differentially expressed genes detected by
Affymetrix microarrays at both ages 3 and 12 months were
associated with the immune/inflammatory response (Table 1). In
agreement with the immunohistochemistry data, genes typically
expressed by monocytes/macrophages [Cd14 and Cd36 (Table 2)
and Aif1, Cd68, Csf1r, Ctss, Gbp2, Igtp, Irf7, Mpeg1, and Plk3
(Supplementary Table S3)] were overexpressed mostly at 3 months.
Differential expression of some of these genes was confirmed by
semiquantitative RT-PCR (Supplementary Fig. S2). Of interest was
the up-regulation in Mdr2-KO livers of the neutrophil-specific gene
6 M. Katzenellenbogen et al., in preparation.
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Saa1 and Saa2 encode acute-phase reactants, serum amyloid A
proteins that may stimulate expression and release of tumor
necrosis factor-a (TNF-a) in neutrophils (9) and induce nuclear
factor-nB (NF-nB) transcriptional activity in epithelial cells (10).
Expression of several important regulators and mediators of
immune/inflammatory response, which was not detected by
Affymetrix microarray, was tested by semiquantitative RT-PCR.
Induciblenitricoxidesynthase(geneNos2),amarkerofmacrophage
activation, was not differentially expressed at either age 3 or 12
months; the same was also true for transforming growth factor-h
(data not shown). In contrast, the TNF-a gene was overexpressed in
the livers of Mdr2-KO mice at both ages (Supplementary Fig. S2).
Among the identified up-regulated genes whose products could
potentially be responsible for suppression of macrophage activa-
tion were Lgals1, encoding galectin-1 (11); Axl, encoding receptor
protein-tyrosine kinase and its ligand Gas6 (12); Pparg, encoding
peroxisome proliferator-activated receptor-g (PPAR-g; ref. 13);
Spp1, encoding osteopontin (14); and Slpi, encoding secretory
leukocyte protease inhibitor (15). Overexpression of some of these
genes at 3 months was confirmed by semiquantitative RT-PCR
(Supplementary Fig. S2A).
The Slpi gene, highly up-regulated in the livers of Mdr2-KO mice
at both ages (Table 2), encodes a serine protease inhibitor having
multiple anti-inflammatory activities (15). To confirm its over-
expression and to determine its cellular localization, we did
immunostaining (Supplementary Fig. S3). In Mdr2-KO mice at
3 months, a very strong cytoplasmic staining was observed in
hepatocytes located in the centrolobular areas throughout the liver,
suggesting a role for Slpi in the control of the acute inflammatory
response (Supplementary Fig. S3B).
These results show a clear difference between the two stages of
liver disease in Mdr2-KO mice: the acute stage at age 3 months and
the chronic stage at age 12 months. In the acute stage, intensive
inflammation of portal tracts was associated with massive invasion
of macrophages accompanied by neutrophils. During inflamma-
tion, several adaptive protective mechanisms seemed to have been
activated, including up-regulation of genes whose products may
suppress activation of macrophages and neutrophils. Most of these
genes were also overexpressed at 12 months, when inflammation
was reduced.
Analysis of oxidative stress and antioxidant systems. Gene
expression profiling revealed induction of many genes involved
in response to oxidative stress in the livers of Mdr2-KO mice
especially at age 3 months (Table 2). Some of these genes control
the metabolism of glutathione, a principal antioxidant, and
included the following: several forms of GST (Gsta), glutathione
peroxidase 4 (Gpx4), glutathione synthase (Gss), and one of the
main transcriptional activators of antioxidant genes, Nrf2 (encoded
by the Nfe2l2 gene). Overexpression of Gss and Nfe2l2 genes at
3 months was confirmed by RT-PCR (Supplementary Fig. S2A). To
evaluate the degree of oxidative stress and the total antioxidant
capacity in the livers of Mdr2-KO mice, we measured the levels of
total liver protein oxidation, frequency of deletions in mtDNA,
and ability of liver extracts to inhibit free radical generator-induced
chemiluminescence. No significant difference was found in the
oxidative levels of total liver proteins between Mdr2-KO and
control heterozygous mice at age 12 months, whereas at age
3 months noticeably fewer oxidized proteins were observed in the
livers of Mdr2-KO mice (Fig. 4A).
In parallel, we estimated the frequency of a specific deletion in
mtDNA, which normally appears only with aging (6), or due to
oxidative stress (16). At age 3 months, the deletion was not
detected in either the control heterozygous or Mdr2-KO mice.
At 12 months, the deletion was hardly detected in Mdr2-KO mice
but was abundant in all control mice (Fig. 4C). The total level of
mtDNA in Mdr2-KO mice was only slightly reduced in comparison
with control mice. These data show that in both tested ages there
was no evidence of an increased oxidative stress in Mdr2-KO mice.
We further assessed the total antioxidant capacity of liver tissues
by measuring its inverse variable, the concentration of liver tissue
extract that provided 50% inhibition of luminol-amplified chemi-
luminescence initiated by AAPH. The total antioxidant capacity of
the liver tissue of 3-month-old Mdr2-KO mice was higher than
that of controls; however, this difference was not evident at age
12 months (Fig. 4B). The first two parts of Fig. 4 are remarkably
similar, thus reflecting the inverse relation between the total
antioxidant capacity of a tissue and the degree of its total protein
oxidation. Similarly, cyclic voltammetry analysis (17) revealed
decreased total antioxidant capacity of the liver tissue extract
aqueous phase obtained from the 12-month-old Mdr2-KO mice
compared with 3-month-old animals (data not shown).
These data show an increased expression of oxidative stress/
antioxidant genes, reduced protein oxidation, and increased total
antioxidant capacity of liver tissues in 3-month-old Mdr2-KO mice.
Figure 1. Age-associated physiologic changes in Mdr2-KO mice. A, levels
of liver enzymes in serum (units). ALT, alanine aminotransferase; ALP/4,
alkaline phosphatase level divided to 4(to fit to the scale); AST, aspartate
aminotransferase. B, liver-to-body weight (%). C, number of visible hepatocyte
mitoses per 20 high-power fields (HPF). Columns, mean of four males; bars,
SD. *, P < 0.05, compared with 3-month-old mice; **, P < 0.01, compared
with heterozygous control; ***, P < 0.01, compared with 3- and 6-month-old mice.
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mice was overexpression of some oxidative stress/antioxidant
genes. These observations suggest an induction of protective
antioxidant systems in the livers of Mdr2-KO mice at an early age
most probably due to a response to oxidative stress caused by
defects in bile metabolism and/or by inflammation.
Lipid metabolism. Steatoticfoc i were observed in the livers of
Mdr2-KO mice at age 12 months (Fig. 2A) but not at age 3, 6, or
9 months. Many genes that control metabolism of lipids and fatty
acids were differentially expressed in the livers of Mdr2-KO mice
according to microarray data (Tables 1 and 2). Some were up-
regulated in Mdr2-KO mice at both ages (ApoA4, ApoC2, Cd36, Lpl,
Pparg, and Ptgds) and others were only up-regulated at 12 months
(Cav1, Cav2, Chka, Fabp4, Fasn, Pdk4, Pld1, Scd1, and Scd2).
Gene Ptgds was strongly up-regulated in the livers of Mdr2-KO
mice at both ages but more significantly at age 12 months (Table 2).
It encodes the key enzyme for production of the proinflammatory
prostaglandin D2, whose secondary derivative, 15-deoxy-D12,14-
prostaglandin J2 (15d-PGJ2), has antiproliferative and anti-
inflammatory activities. Prostaglandin 15d-PGJ2 is a natural ligand
of the PPAR-g receptor, and some of its physiologic effects are
mediated through PPAR-g (18).
Up-regulation of several PPAR-g target genes (Fabp4, Cav1, Cav2,
Cd36, Pdk4, Lpl, and Scd1) in the microarray (Table 2) as well as
validation of Pparg up-regulation by RT-PCR in 3- and 12-month-
old Mdr2-KO mice (Supplementary Fig. S2) support the notion
that PPAR-g signaling pathways are activated in Mdr2-KO mice
especially at age 12 months. The prosteatotic role of PPAR-g in
mouse liver was shown previously by development of liver steatosis
in mice that overexpress it, specifically in the liver (19), and by
significant reduction of hepatic steatosis in two mouse models with
liver-specific deletion of its gene (20, 21). Similarly, liver-specific
expression of the gene Lpl, encoding lipoprotein lipase, resulted
in the uptake of circulating triglycerides and development of
hepatosteatosis (22). In general, Lpl is not expressed in adult liver;
however, it can be induced by TNF-a or by activation of PPAR-g
(22). Lpl is also activated by apolipoproteins C-II and A-IV, the only
two apolipoproteins that were overexpressed in Mdr2-KO mice at
both ages (Table 2).
Phosphatidylcholine metabolism. Several genes involved in
the regulation of phosphatidylcholine metabolism were differen-
tially expressed in Mdr2-KO mice at different stages of the disease.
In 3-month-old Mdr2-KO mice, down-regulation of the last enzyme
in phosphatidylcholine biosynthetic pathway (encoded by gene
Chpt1) and up-regulation of one of the first enzymes to degrade
phosphatidylcholine (two subunits of phospholipase C, encoded
by genes Plce1 and Plcg2) was observed at mRNA level (Table 2).
In 12-month-old Mdr2-KO mice, mRNA levels for these enzymes
were similar to those in controls; however, gene Pld1, encoding
another phosphatidylcholine-degrading enzyme, phospholipase D1,
Figure 2. Histologic analysis of the livers of
Mdr2-KO and healthy control Mdr2(+/) mice.
A, steatotic nodule in the liver of a 12-month-old
Mdr2-KO mouse. Magnification, 40( left) and
100 (right). B, inflammatory patterns in the livers
of Mdr2-KO and control Mdr2(+/) mice at
age 3 months. Top, H&E-stained sections of liver
tissue showing normal portal tract morphology
in a control mouse (left) and bile duct proliferation,
inflammatory cell infiltration, and fibrosis in
the Mdr2-KO mouse (right). Bottom, liver
tissue sections stained with F4/80 monocyte/
macrophage-specific antibody showing staining of
only Kupffer cells in the liver of a control mouse
(left) and intense infiltration of portal tracts
and increased numbers of F4/80-positive cells
in the liver of a Mdr2-KO mouse (right).
Magnification, 100 (top) and 200 (bottom).
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activated by small GTPases of the ARF family. In the Mdr2-KO
livers, the Arf6 gene was up-regulated especially at age 12 months
(Table 2). Gene Chka, encoding a known oncogene, choline kinase
A (23), was up-regulated in 12-month-old Mdr2-KO mice at mRNA
level (Table 2). This was confirmed also by semiquantitative RT-
PCR (Supplementary Fig. S2B). Products of phosphatidylcholine
degradation by phospholipases are known signaling molecules
that participate in the regulation of many cellular responses; in
particular, diacylglycerol activates protein kinase C isoforms that
regulate cell cycling (24). Interestingly, gene Prkcd, encoding the y
isoform of protein kinase C, was up-regulated in Mdr2-KO mice at
both ages (Table 2).
Markers of cell cycle and proliferation. Gene expression
profiling revealed a significant group of genes controlling the
process of DNA replication that were overexpressed in Mdr2-KO
Table 1. Functional groups of differentially expressed genes
Gene group No. differentially expressed genes (3/12 mo)
Total Up-regulated Down-regulated
Apoptosis 44/23 33/22 11/1
Oxidative stress/antioxidant 18/10 15/8 3/2
Immune/inflammatory response 85/41 67/38 18/3
Oncogene 27/17 15/13 12/4
Tumor suppressor/antioncogene 16/11 13/11 3/0
Cell cycle 53/21 40/19 13/2
Signal transduction 76/47 53/34 23/13
Proteolysis 36/28 28/25 8/3
Extracellular matrix 26/18 23/18 3/0
Cholesterol metabolism/biosynthesis 13/5 9/3 4/2
Fatty acid metabolism/biosynthesis 18/10 10/6 8/4
Lipid metabolism/synthesis/transport 34/25 21/20 13/5
Mitochondrion 22/8 8/5 14/3
Cytoskeleton 45/27 38/25 7/2
Cell adhesion 51/35 44/31 7/4
Total 729/373 442/290 287/83
NOTE: Threshold for differential expression is at least 2-fold. Gene groups were determined according to gene annotations that were downloaded by our
program from the main gene databases (LocusLink, GeneAtlas, etc.).
Figure 3. Results of gene expression profiling. A, sample
clustering dendrogram produced by the SPC algorithm.
The Mdr2-KO data set has been preprocessed by filtering of
the valid Affymetrix probes with SD filter. The 8,200
probes whose SD for log2-transformed values all over the
samples was >2.5 were used in SPC clustering. Y axis,
‘‘temperature,’’ the sensitivity variable in SPC clustering
algorithm. B, number of Affymetrix probes differentially
expressed in 3- and 12-month-old Mdr2-KO mice with
1.8-fold threshold. , Total; 5, Up; n, Down.
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DE at
12 mo
DE at
3m o
Gene
symbol
Gene name Functional groups Hepatocellular
carcinoma-associated
expression pattern
Inflammation Oxidative
stress
Lipid/
phospholipid
metabolism
Cell
cycle
Oncogenesis
3.18 2.17 ApoA4 ApolipoproteinA-IV 
2.35 1.97 ApoC2 ApolipoproteinC-II 
2.69 1.92 Arf6 ADP-ribosylationfactor 6 
4.68 6.65 Axl AXL receptor tyrosine kinase 
2.16 1.47 Cav1 Caveolin, caveolae protein 1 
2.85 1.67 Cav2 Caveolin, caveolae protein 2 
2.57 3.50 Ccnd1 Cyclin D1  
0.73 0.49 Ccne1 Cyclin E1 
1.95 1.15 Ccng2 Cyclin G2 
6.90 6.47 Cd14 CD14 antigen 
7.62 8.05 Cd36 CD36 antigen  
1.04 2.13 Cdk4 Cyclin-dependent kinase 4 
4.09 3.22 Cdkn2c Cyclin-dependent kinase
inhibitor 2C (p18, Cdk4 inhibitor)

2.62 0.59 Chka Choline kinase A 
0.74 0.46 Chpt1 Choline phosphotransferase 1
(diacylglycerol)

2.34 4.49 Copeb KLF6 
2.73 4.95 Cyba Cytochrome b-245, a polypeptide 
2.04 1.53 Ets2 E26 avian leukemia oncogene 2 
5.25 1.00 Fabp4 aP2; fatty acid–binding protein 4 
1.85 1.29 FasnFatty acid syn thase 
1.80 2.30 Fos FBJ osteosarcoma oncogene 
1.93 2.38 Gas6 Growth arrest specific 6 
1.91 2.27 Gpx4 Glutathione peroxidase 4 
1.32 1.80 Gss Glutathione synthetase 
2.33 2.61 Gsta2 Glutathione S-transferase, a2 
2.01 1.58 Gsta4 Glutathione S-transferase, a4 
5.26 4.96 Gstm3 Glutathione S-transferase, l3 
5.80 4.33 Jun Jun oncogene 
31.17 46.44 Lcn2 Lipocalin 2 
3.46 3.54 Lgals1 Lectin, galactose binding, soluble 1 
3.53 3.53 Lgals3 Lectin, galactose binding, soluble 3 
4.85 4.60 Lpl Lipoproteinlipase 
1.52 1.80 Nfe2l2 Nrf2 transcriptional factor 
1.67 2.19 Nras Neuroblastoma ras oncogene 
1.51 2.81 Pcna Proliferating cell nuclear antigen 
6.74 1.20 Pdk4 Pyruvate dehydrogenase kinase,
isoenzyme 4

1.54 2.19 Plce1 Phospholipase C, e1 
0.90 1.83 Plcg2 Phospholipase C, c2 
1.95 1.70 Pld1 Phospholipase D1 
0.55 1.25 Ppara Peroxisome proliferator-activated
receptor a

2.00 1.80 Pparg Peroxisome proliferator-activated
receptor c

2.36 2.09 Prkcd Proteinkin ase C, d 
8.76 4.33 Ptgds Prostaglandin D2 synthase (brain) 
1.98 3.24 Rras Harvey rat sarcoma oncogene,
subgroup R

1.81 1.40 Rras2 Related Ras viral (r-ras)
oncogene homologue 2

6.68 8.32 S100a11 S100c; calcium-binding protein A11 
3.21 6.06 Saa1 Serum amyloid A1 
(Continued on the following page)
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This group included six minichromosome maintenance proteins
responsiblefor‘‘chromatinlicensing’’(25),cyclin-dependentkinase4
(Cdk4), and proliferating cell nuclear antigen (PCNA), a known
proliferationmarker.Immunohistochemicalstainingconfirmedthat
PCNA was significantly up-regulated in the livers of 3-month-old
Mdr2-KO mice (Supplementary Fig. S4B compared with Supple-
mentary Fig. S4A) but only slightly up-regulated in 12-month-old
mutants (Supplementary Fig. S4D compared with Supplementary
Fig. S4C). PCNA was mostly detected in hepatocytes, showing that
DNA replication takes place mainly in Mdr2-KO hepatocytes.
However, when hepatocyte mitoses were directly counted on
histologicsections,significanthepatocyteproliferationwasdetected
onlyin9- and12-month-oldMdr2-KOmice(Fig.1C).IncreasedDNA
replication without hepatocyte mitoses in 3-month-old Mdr2-KO
mice could be explained by hepatocyte cell cycle arrest. A possible
regulator responsible for this effect is nuclear phosphoprotein
S100A11/S100c(26)thatwassignificantlyoverexpressedinMdr2-KO
livers at both ages 3 and 12 months (Table 2).
Expression of cyclin D1, a key regulator of cell cycle progression
and a known oncogene, was significantly increased at mRNA level
in the livers of both 3- and 12-month-old Mdr2-KO mice (Table 2).
Overexpression of cyclin D1 protein was also confirmed by Western
blot analysis of liver extracts from Mdr2-KO and control mice
(Fig. 4D). Two inhibitors of the cyclin D1-Cdk4/6 complex activity
were overexpressed at mRNA level in Mdr2-KO livers at both ages
(Table 2): p18Ink4c, encoded by the gene Cdkn2c, and KLF6,
encoded by the gene Copeb (27).
These results suggest that hepatocyte replication in Mdr2-KO
mice at an early stage of liver disease is blocked by multiple
protective mechanisms. However, between ages 6 and 9 months,
these protective mechanisms fail, resulting in intensive hepatocyte
proliferation leading to the development of multiple dysplastic
nodules by age 12 months.
Oncogenes and tumor suppressors. Gene expression profiling
revealed a significant number of oncogenes and tumor suppressors
thatwere differentially expressed (mainly up-regulated) in Mdr2-KO
mice at both ages (Table 1). The most prominent was the Ras family
of proteins: Nras, Rras, and Rras2 (Table 2) and Rhob, Rhoc, Rhod,
and Rhoe (Supplementary Table S3). Genes Lgals1 and Lgals3,
encoding known activators of Ras signaling, galectin-1 and
galectin-3, which augment activation of H-Ras and K-Ras, respec-
tively(28,29),werealsooverexpressedinMdr2-KOmiceatbothages
(Table2).Thus,wetestedthelevelsofRasproteinsandactivatedRas
(Ras-GTP complexes) in mouse liver extracts by immunoblotting
withPan-Rasantibody (detectsH-Ras,N-Ras,andK-Ras)or withanti-
R-Ras antibody (detects R-Rasonly). Ina pull-down assay ofactivated
Ras proteins, the detection was done only with Pan-Ras antibody.
As can be seen in Fig. 4D, the average level of the Ras isoforms
detected by the Pan-Ras antibody was higher in Mdr2-KO mice
at both ages. However, levels of the activated Ras in Mdr2-KO
mice were not higher than those in controls at any age: at age
12 months, they were comparable, whereas at age 3 months they
varied from equal to significantly lower than in controls (seven
3-month-old Mdr2-KO mice produced similar results). Thus, results
inferred partial suppression of Ras activation in 3-month-old Mdr2-
KO mice and restoration of Ras activation to normal levels by age
12 months. Levels of the R-Ras protein in Mdr2-KO livers were
significantly lower than in controls at both ages despite
confirmation of the up-regulation of R-Ras mRNA by semiquan-
titative RT-PCR at both ages 3 and 12 months (data for 3-month-
old mice are shown in Supplementary Fig. S2A).
Up-regulation of genes Jun and Fos, encoding two components
of the transcription factor activator protein-1 (AP-1), c-Jun and
c-Fos, was detected in Mdr2-KO mice at both ages by microarray
(Table 2) and by RT-PCR (Supplementary Fig. S2) techniques. The
critical role of the c-Jun proto-oncoprotein in hepatocellular
carcinoma development was recently shown on a mouse model
of chemically induced hepatocarcinogenesis (30). On the other
hand, its functional antagonist, transcription factor KLF6, encoded
by the gene Copeb (31), was also found to be up-regulated in Mdr2-
KO mice at both ages (Table 2).
Discussion
In the present study, we did detailed gene expression, histologic,
and biochemical analyses to identify potentially important
regulators that function at the early stages of hepatocellular
2.00 3.59 Saa2 Serum amyloid A2 
2.60 1.42 Scd1 Stearoyl-CoA desaturase 1 
4.00 1.40 Scd2 Stearoyl-CoA desaturase 2 
10.70 17.98 Slpi Secretory leukocyte protease
inhibitor

1.41 2.50 Sod3 Superoxide dismutase 3, extracellular 
1.90 2.20 Spp1 Osteopontin, secreted phosphoprotein 1 
1.81 3.93 Stat1 Signal transducer and activator
of transcription 1

NOTE: Listed are genes that had differential expression (DE) at least 1.8-fold (mean of Mdr2-KO mice relative to the mean of control Mdr2-
heterozygotes) at age 3 or 12 months.
Table 2. Genes differentially expressed in the livers of Mdr2-KO mice at age 3 or 12 months (Cont’d)
DE at
12 mo
DE at
3m o
Gene
symbol
Gene name Functional groups Hepatocellular
carcinoma-associated
expression pattern
Inflammation Oxidative
stress
Lipid/
phospholipid
metabolism
Cell
cycle
Oncogenesis
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liver disease in Mdr2-KO mice at the precancerous stage is
characterized by a cross-talk between regulatory systems that
control immune response, oxidative stress, hepatocyte prolifera-
tion, and lipid metabolism. These data suggest that multiple
adaptive mechanisms have been induced in each of these systems
to cope with primary genetic defect and its physiologic con-
sequences in this hepatocellular carcinoma model.
One of the central issues for this model is the role of the immune
response in hepatocarcinogenesis. Recently, in this model, the
important role of TNF-a and NF-nB in promoting hepatocellular
carcinoma development was shown (32). Here, we describe massive
infiltrationofmonocytes/macrophagesandneutrophilsintheportal
tracts and liver parenchyma of 3-month-old Mdr2-KO mice, which
was reduced butwas still present at age 12 months. However, mRNA
of inducible nitric oxide synthase was not up-regulated at both ages,
indicating possible suppression of macrophage activation. Several
geneswhoseproductsmayaccomplish thisprotective functionwere
found to be up-regulated in the livers of both 3- and 12-month-old
Mdr2-KO mice: Axl, Gas6, Lgals1, Pparg, Slpi, and Spp1 (11–15).
Similarly, mRNA of TNF-a and serum amyloid proteins, A1 and A2,
were overexpressed in the livers of Mdr2-KO mice at both ages
(SupplementaryFig.S2;Table2);thesefactorsmayactivateNF-nBin
epithelial cells (10, 32), a response that may protect mature
hepatocytes against immune attack and biological stress (33).
However,manyofthesegeneproductsthatarepotentiallyprotective
against inflammation could also promote hepatocarcinogenesis
(11, 34). The antiapoptoticeffec t of NF- nB on hepatocytes has been
shownintheMdr2-KOmodel(32).However,inachemicallyinduced
liver cancer model, it was recently shown that NF-nB induction in
hepatocytes is antitumorigenic, whereas in Kupffer cells it is
procarcinogenic (35). Thus, the actual role of NF-nB activation in
hepatocarcinogenesis in this hepatocellular carcinoma model
requires further elucidation.
Oxidative stress has long been implicated in carcinogenesis. It is
known that reactive oxygen species activate signal transduction
pathways, including AP-1 and NF-nB, and cause oxidative DNA
damage, increasing risk of cancer development (36). We could not
detect signs of increased oxidation of total liver protein or of
mtDNA in Mdr2-KO mice. However, up-regulation of the Cyba gene
encoding the critical component of the membrane-bound oxidase
of phagocytes that generates superoxide (Table 2) indicates that
reactive oxygen species are produced in the inflamed livers of
Mdr2-KO mice at both studied ages.
Results of this study revealed a significant number of dysplastic
nodules in the livers of 12-month-old Mdr2-KO mice. We suggest
that both intensive hepatocyte death and compensating prolifera-
tion takeplace intheirlivers. This death mayresulteither from toxic
Figure 4. Analysis of the liver tissues of Mdr2-KO and
control Mdr2(+/) mice. A, mean relative levels of
protein oxidation in different experimental groups (three
males in each group) measured with the Oxyblot kit
as described in Materials and Methods. B, concentrations
of liver tissue extracts (mg/mL; mean of three males
per each experimental group) producing 50% inhibition
of AAPH-induced luminol-amplified chemiluminescence
(as described in Materials and Methods). The total
antioxidant capacity of liver tissue is inversely
proportional to the IC50 of liver extract. *, P <0 . 0 5 ,
compared with age-matched heterozygous control. C,
detection of the deletions in mtDNA by semiquantitative
RT-PCR in 12-month-old mice (three males per each
group). mtD1, DNA fragment corresponding to the
unstable region of mtDNA that is frequently deleted
in aging or at oxidative stress; mtDNA, DNA
fragment corresponding to a stable region of mtDNA.
D, immunoblot analysis of liver tissue extracts from
3-month-old (left) or 12-month-old (right)M d r 2 - K O
and control heterozygous mice. Pan-Ras antibody
revealed two main bands in immunoblots of liver extracts
[f21 (bottom)a n d2 4( top) kDa]. At age 3 months,
Ras was detected mostly in the bottom band, whereas at
age 12 months Ras was detected mostly in the top band.
Ras-GTP complexes were immunoprecipitated with
GST-Raf1-RBD as described in Materials and Methods
and immunoblotted with Pan-Ras antibody.
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hepatocyte injury (e.g., reactive oxygen species produced by
infiltrating phagocytes) or due to overrun of cell protective
mechanisms after age 6 months. The increased hepatocyte
proliferation may elevate hepatocellular carcinoma incidence by
accumulation of spontaneous mutations during normal DNA
replication (37).
In the present work, one of the most prominent features
discovered in the Mdr2-KO mice is overexpression in their livers of
cyclin D1, a known oncogene that is also overexpressed in the early
stages of many types of human tumors (38). In many cancer types,
including hepatocellular carcinoma, cyclin D1 overexpression is
associated with poor prognosis (39). Supporting its critical role in
hepatocarcinogenesis, transgenic mice that overexpress cyclin D1,
specifically in the liver, developed hepatocellular carcinoma (40),
whereas antisense oligonucleotides to cyclin D1 inhibited growth of
hepatoma cells (41). Up-regulation of c-Jun in the Mdr2-KO livers
that was shown in our laboratory by both microarray and RT-PCR
and earlier by immunohistochemistry (32) is of significance to liver
cancer development not only due to up-regulation of cyclin D1 by c-
Jun but also because c-Jun itself promotes liver cancer in mice by
antagonizing p53 activity (30). Supporting the increased activity of
c-Jun is the recent finding that livers of Mdr2-KO mice overexpress
thec-JunNH2-terminalkinase(32),whichisresponsibleforcyclinD1
expression and hepatocyte proliferation during liver regeneration.
Oneofthe moststriking featuresof liverdiseaseinMdr2-KO mice
is slowly developing liver steatosis. Analysis of underlying molecular
mechanisms suggests a key role of PPAR-g in this process. Although
the Pparg gene was overexpressed in Mdr2-KO mice at both ages,
dynamics of expression of its target genes showed that it was
activated preferentially at age 12 months. This correlates with the
increased overexpression at this age of prostaglandin synthase D2
(gene Ptgds) that should produce increased levels of prostaglandin
15d-PGJ2, a natural PPAR-g ligand. Up-regulation of adipocyte-
specific PPAR-g-regulated genes (e.g., Fabp4) shows that steatosis
developed in Mdr2-KO mice may be characterized as ‘‘adipogenic
hepaticsteatosis’’ or ‘‘hepaticadiposis’’ (19).
Besides its role in lipid metabolism, PPAR-g is also involved in
the regulation of processes important for cancer development:
response to oxidative stress (42), inflammation (43), and regulation
of cell cycle (44). Its target gene, Cd36, links lipid metabolism to
oxidative stress (45); it was strongly up-regulated in the livers of
Mdr2-KO mice at both ages (Table 2).
Our results revealed up-regulation in Mdr2-KO mice of mRNA
of the enzymes metabolizing phosphatidylcholine: phospholipase C
at 3 months and phospholipase D1 and choline kinase A at 12
months. These changes may have a profound effect on hepatocarci-
nogenesis. Activation of choline kinase A has been recently found to
be a critical factor for mammary epithelial cell proliferation and
breast tumor progression (23). Among all oncogenes differentially
expressed in the liver of Mdr2-KO mice, choline kinase A was the
only one exclusively up-regulated at age 12 months. This expression
pattern suggeststhat choline kinase A may playan important role in
hepatocarcinogenesis in Mdr2-KO mice. The products of phospha-
tidylcholine degradation by phospholipases D and C, phosphatidic
acid and diacylglycerol, act as second messengers essential for
mitogenic activity of growth factors. It is known that phosphatidyl-
choline hydrolysis may activate the Ras-Raf1-mitogen-activated
protein kinase (MAPK) cascade downstream of Ras but upstream of
Raf1 (46). Diacylglycerol may activate protein kinase C (24). Protein
kinase Cy, which was up-regulated in Mdr2-KO mice at both ages, is
capable of both positive and negative regulation of cell proliferation
and may be activated by TNF-a and oxidative stress (24, 47).
Although we found no evidence of Ras activation in the livers of
Mdr2-KO mice at both ages, the Ras-Raf1-MAPK signaling pathway
may be activated in this model by products of phosphatidylcholine
metabolism and by TNF-a downstream of Ras. Interestingly, similar
phenotypes and mechanisms characterize hepatocarcinogenesis in
rats supplied with choline-deficient diet: fatty liver, increased levels
of phosphatidylcholine metabolism, sustained activation of protein
kinase C, and increased level of protein kinase Cy (48, 49). However,
in contrast to the Mdr2-KO model, the choline-deficient diet is
effective only for males in both rats and mice.
In conclusion, we found induction of multiple adaptive
mechanisms to chronic liver disease in Mdr2-KO mice in both
early and late precancerous stages, which could protect the liver
from inflammation, oxidative stress, and uncontrolled hepatocyte
proliferation. However, prolonged overexpression of these mecha-
nisms could have an effect on liver cancer development in
these mice. We have identified significant disturbances in lipid
and phosphatidylcholine metabolism that may cause activation of
oncogenic pathways. Finally, we have shown overexpression in the
livers of Mdr2-KO mice of cyclin D1 protein, a key oncogene, which
may be a good candidate for functional KO experiments in this
hepatocellular carcinoma model. It should be mentioned that the
use of whole liver extracts for gene expression profiling is only the
first step in determining the roles of the differentially expressed
genes discussed above in hepatocellular carcinoma development.
More detailed knowledge concerning the role of these genes in
hepatocarcinogenesis in Mdr2-KO mice should be further eluci-
dated by immunohistochemical determination of cell type
specificity, cytoplasmic/nuclear localization, and local expression
pattern of the appropriate proteins and by comparative gene
expression profiling of tumorous versus nontumorous liver tissues.
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